布地奈德/福莫特罗粉吸入剂治疗AECOPD的疗效分析

Effect of Budesonide/Formoterol Inhaling Treatment on Acute Exacerbations of Chronic Obstructive Pulmonary Disease

目的观察布地奈德/福莫特罗粉吸入剂治疗慢性阻塞性肺疾病急性加重期(AECOPD)的效果。方法 98例AECOPD住院患者,随机分为两组,对照组49例给予常规治疗,治疗组49例给予常规治疗的同时,吸入布地奈德/福莫特罗粉吸入剂,每日2次。对比治疗后患者第一秒用力呼气容积(FEV1)占预计值百分比(FEV1%)、第一秒用力呼气容积与用力肺活量比值(FEV1/FVC)及圣乔治呼吸问卷(SGRQ)分值的变化。结果 FEV1、FEV1%、FEV1/FVC与呼吸问卷分值比较,治疗组治疗后比较治疗前明显升高,差异有统计学意义(P<0.05);对照组治疗后比较治疗前亦均有明显升高(P<0.05),但对照组的改善情况不如治疗组(P<0.05)。结论布地奈德/福莫特罗粉吸入疗法对AECOPD疗效肯定,可改善肺功能并提高生活质量,可作为治疗AECOPD的有效方案。

Objective To investigate the effect of budesonide/formoterol fumarate powder for inhalation treatment on the acute exacerbations of chronic obstructive pulmonary disease （AECOPD）.Methods Totally 98 subjects with AECOPD were divided into two groups randomly.Baseline treatment was equal in all patient.On the base of routine therapy of control group （49 cases）,the trial group （49 cases） received budesonide/formoterol （160μg/4.5μg） inhalation twice a day additionally.Compare the difference of two groups at FEV1,FEV1%,FEV1/FVC and the scores of SGRQ before and after the therapy.Results The FEV1,FEV1%,FEV1/FVC and the scores of SGRQ in both groups were improved in evidence （P0.05）,and the trial group were better than the control group （P0.05）.Conclusion Budesonide/formoterol fumarate powder for inhalation can improve the pulmonary function and quality of life of the AECOPD patients and should be popularized as an effective method.